Notably, prior work has suggested thatBAP1, PBRM1, and ARID1Adeficiency all result in sensitivity to EZH2 inhibition across cancer types (Kim et al., 2015; LaFave et al., 2015); the association of ARID1Amethylation with IDH mutation opens the question of whether EZH2 inhibition mightalso be effective in this subtype. Here, IDH2 is linked to cancer.